特发性全面性癫痫治疗反应模式与预后标志物
该研究分析了328例成人特发性全面性癫痫患者,评估其治疗反应模式及常规临床与神经生理参数能否预测拉莫三嗪、左乙拉西坦或丙戊酸的反应。结果显示首次尝试即达无发作且副作用可接受者仅18.6%,三种药物反应率存在差异,但校正药物抵抗后常规临床参数并不能指示特定药物的反应。
要点
- 首次单药治疗即达无发作且副作用可接受者仅18.6%。
- 丙戊酸反应率较高但副作用风险也较高,保留率低。
- 常规临床参数不能预测特定抗癫痫药物的反应。
核心结论
- 尽管癫痫控制率较高,但首次尝试即达无发作且副作用可接受的机会较低,源于常用三种药物疗效与副作用呈反向关联。
- 常规评估的临床参数不能指示对特定抗癫痫药物的反应。
研究设计与样本
- 回顾性分析328例成人特发性全面性癫痫患者的病历和访谈数据,收集人口学、影像、脑电图、当前及既往抗癫痫治疗、治疗结局和副作用。
主要发现
- 61例(18.6%)患者首次尝试即达无发作且副作用可接受。
- 拉莫三嗪、左乙拉西坦和丙戊酸的反应率分别为39.8%、47.5%和71.1%,在青少年肌阵挛癫痫患者中差异最明显。
- 丙戊酸副作用风险为23.7%,高于拉莫三嗪的10.4%和左乙拉西坦的20.4%,导致丙戊酸保留率低至53.7%。
- 治疗抵抗与已知危险因素相关;校正药物抵抗后,多变量分析未发现预测特定药物反应的临床指标。
关键数值与推荐
- 拉莫三嗪反应率39.8%,左乙拉西坦47.5%,丙戊酸71.1%。
- 丙戊酸副作用风险23.7%,拉莫三嗪10.4%,左乙拉西坦20.4%。
- 丙戊酸保留率53.7%。
- 该研究提供Class II证据:特发性全面性癫痫患者的各种临床因素不能预测特定抗癫痫药物的反应。
临床怎么用
- 对特发性全面性癫痫患者,选择抗癫痫药物时需权衡疗效与副作用,不能仅凭常规临床参数预测个体对特定药物的反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the pattern of treatment response in patients with idiopathic generalized epilepsy (IGE) and whether routinely assessed clinical and neurophysiological parameters allow predicting response to lamotrigine, levetiracetam, or valproic acid. METHODS: In 328 adult patients with IGE, demographic data, imaging, EEG data, current and prior antiepileptic treatment, treatment outcome, and side effects were analyzed from the patients' medical files and patient interviews. RESULTS: Seizure freedom with acceptable side effects at the first attempt was achieved in 61 (18.6%) patients. One hundred four (31.7%) patients tried ≥3 antiepileptic drugs before achieving seizure control at the last follow-up. Lamotrigine, levetiracetam, and valproic acid showed differential response rates (39.8% vs 47.5% vs 71.1%) that were most pronounced in patients with juvenile myoclonic epilepsy. The risk of having side effects was higher with valproic acid (23.7%) than with lamotrigine (10.4%) or levetiracetam (20.4%) treatment, contributing to the low retention rate of valproic acid (53.7%). Treatment resistance was associated with established risk factors. Multivariate analyses aiming at identifying clinical indicators for response to specific drugs did not reveal putative biomarkers when corrected for drug resistance. CONCLUSION: Despite a high rate of seizure control, the chance of achieving seizure control and acceptable side effects at first attempt was low due to an inverse association of effectiveness and side effects of the 3 most commonly used drugs. Routinely assessed clinical parameters were not indicative for response to specific drugs. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with IGE, various clinical factors do not predict a response to specific antiepileptic drugs.
引用
- Gesche J, Hjalgrim H, Rubboli G, et al. Patterns and prognostic markers for treatment response in generalized epilepsies. Neurology. 2020. PMID: 32817177. doi:10.1212/WNL.0000000000010644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。